Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 7.31 -0.04 (0.54%)
Day High: 7.38
Day Low:  7.26
Volume:    59,220
10:30 AM ET
May 23, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

May 31, 2017 / 10:00 AM ET
Apr 4, 2017 / 10:00 AM ET